S
42.76
-0.04 (-0.09%)
| Previous Close | 42.80 |
| Open | 42.33 |
| Volume | 1,174,461 |
| Avg. Volume (3M) | 2,122,566 |
| Market Cap | 4,361,838,592 |
| Price / Sales | 13.14 |
| Price / Book | 18.22 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (UBS, 40.32%) | Buy |
| Median | 49.50 (15.76%) | |
| Low | 42.00 (Wolfe Research, -1.78%) | Buy |
| Average | 50.00 (16.93%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 39.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 09 Jan 2026 | 55.00 (28.62%) | Buy | 42.18 |
| UBS | 07 Jan 2026 | 60.00 (40.32%) | Buy | 44.23 |
| Barclays | 17 Dec 2025 | 52.00 (21.61%) | Buy | 44.01 |
| 17 Nov 2025 | 45.00 (5.24%) | Buy | 36.47 | |
| JP Morgan | 18 Nov 2025 | 47.00 (9.92%) | Buy | 39.81 |
| Wolfe Research | 18 Nov 2025 | 42.00 (-1.78%) | Buy | 39.81 |
| Truist Securities | 20 Oct 2025 | 44.00 (2.90%) | Buy | 27.92 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Announcement | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 13 Dec 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Nov 2025 | Announcement | Scholar Rock to Present at Upcoming Investor Conferences |
| 14 Nov 2025 | Announcement | Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Announcement | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference |
| 23 Oct 2025 | Announcement | Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 |
| 17 Oct 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |